ALIM vs. GLSI, GALT, RIGL, GOSS, CAPR, PRLD, SCPH, PRQR, LFCR, and TELO
Should you be buying Alimera Sciences stock or one of its competitors? The main competitors of Alimera Sciences include Greenwich LifeSciences (GLSI), Galectin Therapeutics (GALT), Rigel Pharmaceuticals (RIGL), Gossamer Bio (GOSS), Capricor Therapeutics (CAPR), Prelude Therapeutics (PRLD), scPharmaceuticals (SCPH), ProQR Therapeutics (PRQR), Lifecore Biomedical (LFCR), and Telomir Pharmaceuticals (TELO). These companies are all part of the "pharmaceutical preparations" industry.
Greenwich LifeSciences (NASDAQ:GLSI) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability, community ranking and earnings.
Greenwich LifeSciences has a net margin of 0.00% compared to Greenwich LifeSciences' net margin of -23.74%. Greenwich LifeSciences' return on equity of -53.49% beat Alimera Sciences' return on equity.
4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 99.8% of Alimera Sciences shares are owned by institutional investors. 52.9% of Greenwich LifeSciences shares are owned by insiders. Comparatively, 31.4% of Alimera Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Greenwich LifeSciences has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Comparatively, Alimera Sciences has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.
Greenwich LifeSciences has higher earnings, but lower revenue than Alimera Sciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Alimera Sciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Alimera Sciences had 15 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 16 mentions for Alimera Sciences and 1 mentions for Greenwich LifeSciences. Alimera Sciences' average media sentiment score of 0.59 beat Greenwich LifeSciences' score of -0.16 indicating that Greenwich LifeSciences is being referred to more favorably in the media.
Alimera Sciences received 351 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 57.70% of users gave Alimera Sciences an outperform vote while only 33.33% of users gave Greenwich LifeSciences an outperform vote.
Greenwich LifeSciences presently has a consensus target price of $36.00, indicating a potential upside of 157.51%. Alimera Sciences has a consensus target price of $8.00, indicating a potential upside of 150.00%. Given Alimera Sciences' higher probable upside, equities analysts clearly believe Greenwich LifeSciences is more favorable than Alimera Sciences.
Summary
Alimera Sciences beats Greenwich LifeSciences on 9 of the 16 factors compared between the two stocks.
Get Alimera Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alimera Sciences Competitors List
Related Companies and Tools
